Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AZD-3463 (ALK/IGF1R inhibitor) 是一种具有口服活性的ALK/IGF1R 抑制剂,对 ALK 作用的Ki 值为 0.75 nM。它可诱导神经母细胞瘤细胞凋亡和自噬。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 196 | 现货 | ||
5 mg | ¥ 455 | 现货 | ||
10 mg | ¥ 690 | 现货 | ||
25 mg | ¥ 1,490 | 现货 | ||
50 mg | ¥ 2,910 | 现货 | ||
100 mg | ¥ 4,290 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 493 | 现货 |
产品描述 | AZD-3463 (ALK/IGF1R inhibitor) , an orally bioavailable ALK inhibitor (Ki: 0.75 nM), can inhibit IGF1R with equivalent potency. |
靶点活性 | ALK:0.75 nM(Ki) |
体外活性 | 在体内,AZD-3463对突变型L1196M和野生型ALK的作用同等有效.在体内作用于移植瘤时,AZD-3463剂量依赖性抑制pALK,使肿瘤体积停滞(H3122)或衰退(DEL,H2228). |
体内活性 | 在各种体外耐Crizotinib模型中,AZD3463对六分之五的细胞具有抗增殖的效力,4倍于亲本H3122细胞。AZD3463对含ALK融合的肿瘤细胞系均有效果,包括DEL(ALCL NPM-ALK),H2228(NSCLC EML4-ALK)和H3122(NSCLC EML4-ALK),抑制ALK并降低其自身磷酸化。 |
激酶实验 | HDAC enzymatic assays: Tubastatin A is dissolved and diluted in assay buffer (50 mM HEPES, pH 7.4, 100 mM KCl, 0.001% Tween-20, 0.05% BSA, and 20 μM tris(2-carboxyethyl)phosphine) to 6-fold of the final concentration. HDAC enzymes are diluted to 1.5-fold of the final concentration in assay buffer and pre-incubated with Tubastatin A for 10 minutes before the addition of the substrate. The amount of FTS (HDAC1, HDAC2, HDAC3, and HDAC6) or MAZ-1675 (HDAC4, HDAC5, HDAC7, HDAC8, and HDAC9) used for each enzyme is equal to the Michaelis constant (Km), as determined by a titration curve. FTS or MAZ-1675 is diluted in assay buffer to 6-fold the final concentration with 0.3 μM sequencing grade trypsin. The substrate/trypsin mix is added to the enzyme/compound mix and the plate is shaken for 60 seconds and then placed into a SpectraMax M5 microtiter plate reader. The enzymatic reaction is monitored for release of 7-amino-4-methoxy-coumarin over 30 minutes, after deacetylation of the lysine side chain in the peptide substrate, and the linear rate of the reaction is calculated. |
别名 | ALK/IGF1R inhibitor |
分子量 | 448.95 |
分子式 | C24H25ClN6O |
CAS No. | 1356962-20-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 23 mg/mL (51.2 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2274 mL | 11.1371 mL | 22.2742 mL | 55.6855 mL |
5 mM | 0.4455 mL | 2.2274 mL | 4.4548 mL | 11.1371 mL | |
10 mM | 0.2227 mL | 1.1137 mL | 2.2274 mL | 5.5685 mL | |
20 mM | 0.1114 mL | 0.5569 mL | 1.1137 mL | 2.7843 mL | |
50 mM | 0.0445 mL | 0.2227 mL | 0.4455 mL | 1.1137 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AZD-3463 1356962-20-3 Angiogenesis Apoptosis Autophagy Tyrosine Kinase/Adaptors ALK IGF-1R Anaplastic lymphoma kinase (ALK) Anaplastic lymphoma kinase neuroblastoma kinase AZD3463 receptor PI3K/AKT/mTOR. pathway crizotinib CD246 resistance ALK tyrosine kinase receptor Inhibitor inhibit AZD 3463 ALK/IGF1R inhibitor Cluster of differentiation 246 tyrosine inhibitor